As an MSCA Doctoral Network, dIscOverNET aims to implement a higly innovative doctoral program, by partnerships of universities, research institutions and infrastructures, businesses including SMEs, and other socio-economic actors from different countries across Europe and beyond.
This doctoral program will respond to well-identified needs in various research and innovation areas, expose the researchers to the academic and non-academic sectors, and offer research training, as well as transferable skills and competences relevant for innovation and long-term employability.
More information about the Marie Sklodowska-Curie Doctoral Networks can be found on the MSCA website.
Problem Statement
Neuroendocrine neoplasms (NEN) are rare tumors originating from neuroendocrine cells. NEN may develop in various anatomical sites but are mostly found in the gastroenteropancreatic and pulmonary tracts. According to the World Health Organization, NEN can be divided into well-differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC).
The proposed research will focus on NET from the gastroenteropancreatic tract and lung as they make up 94% of all NEN and are clinically and biologically very distinct from NEC. To date, surgery and/or locoregional therapy remains the cornerstone for curative treatment for non-metastasized NET, but recent data and real-world evidence report recurrence rates up to 15-50%. Moreover, 40–50% of NET patients present with distant metastases at initial diagnosis. For these patients, systemic treatment options are used to delay tumor growth, but they do not offer a cure and have limited impact on long-term progression.
Despite a 5-year survival rate of 57%, the current treatment options only manage to stall disease progression and patients ultimately succumb to their disease. While this indicates a high unmet need for better treatment strategies, only 5 of the 116 new cancer treatments approved by the European Medicine Agency in the last decade targeted NET. A remarkable proportion of all new treatment options in other solid tumors is represented by immune-driven strategies, which leverage the immune system's ability to recognize and destroy cancer cells. While these treatment options are transforming the treatment landscape of various other solid tumors, the current generation of immunotherapies, such as immune checkpoint inhibitors (ICI), have only limited efficacy in NET and novel immune-driven strategies are therefore direly needed.
Addressing the Problem
This project will leverage the impactful preclinical research that is currently shaping the immunotherapy field, to systematically adapt and optimize next-generation immune-driven strategies for NET. Both Europe's Beating Cancer Plan (EBCP) and EU Cancer Mission highlight the opportunity of using the EU’s unique position to maximize translational research on rare cancers by enhancing horizontal collaboration and pooling scientific expertise, patient samples, clinical and research data.
With this objective in mind, the dIscOverNET doctoral network brings together leading academic institutions, clinical centers, research infrastructures, and industrial partners with complementary expertise spanning tumor immunology, cell therapy, spatial biology, therapeutic development, preclinical modeling, and clinical translation to advance the field of immunotherapy in NET beyond the current state-of-the-art in other cancer types. We hypothesize that immunotherapy efficacy in NET can be unlocked by developing therapeutic approaches tailored to the unique features of NET, integrating these with tumor-priming strategies through modulation of the tumor immune microenvironment (TIME), and evaluating them in advanced experimental NET models that more faithfully recapitulate physiologically relevant TIME interactions.
Main research objective
The main research objective of dIscOverNET is moving the needle for advanced immune-driven strategies in NET from concept (technology readiness level [TRL] 1) to “ready for clinical validation” (TRL4). This will be achieved by highly innovative scientific work to:
- Accelerate the rational design and implementation of immune-driven therapies that are tailored to the unique biology of NET.This will be done by redefining target identification strategies through applying 3 complementary approaches to discover novel NET-specific (immunogenic) targets as well as by creating target/epitope prioritization pipelines. Moreover, we will develop 3 novel NET-specific immuno-oncology strategies using validated targets and demonstrate their therapeutic efficacy preclinically. (B)
- Demonstrate the potential of prime–to-boost strategies using tumor–immune microenvironment (TIME) modulationTo achieve this, we will perform comprehensive TIME mapping using complementary advanced immunohistochemistry (IHC) and sequencing-based methods and use this data to discover novel, clinically actionable strategies for TIME modulation. Moreover, we will provide proof-of-concept for 4 strategies to prime NET by reversing the immuno-cold signature.(C)
- Develop and validate advanced complementary preclinical platforms capable of addressing immune-driven therapeutic questions.To achieve this, we will harmonize the collection of fresh NET tumor tissue, establish 3 novel in vitro approaches that accurately reproduce tumor–TIME interactions to facilitate medium-throughput screening and functional assays and establish 2 novel in vivo models allowing efficacy testing of novel immune-driven strategies.
The 15 projects
Each position is a separate reserach project, that will be mainly excecuted at its own host institution (with the exception of two secondments at dIscOverNET partner organisations, of a combined duration of 7–10 months).
DC1 - Identification and prioritization of non-canonical immunotherapy targets for NET at MyNEO
Redeploying high-quality transcriptome data to uncover deregulated dark genome elements (long non-coding RNAs [lncRNAs] and small non-coding RNAs), for non-canonical target mining trough MN’s in-house algorithms at MyNEO under the supervision of Dr. Lien Lybaert
Work Plan
Leveraging high-quality transcriptomic data analysis to identify dysregulated elements of the dark genome, particularly non-coding RNAs, with the aim of advancing our understanding of NET biology and uncovering novel non-canonical immunotherapy targets. During a secondment at ICR, the DC will gain in-depth insight into NET molecular biology and hands-on training in identifying targetable immune pathways affected by dysregulated RNAs.
Candidate targets derived from the dysregulated dark genome will be identified and prioritized in silico using myNEO’s proprietary analysis pipeline. The most promising candidates will be cross-validated against peptide-based targets in collaboration with DC2. Finally, the top-ranked targets will be functionally validated in vitro during a secondment at UAntwerp, where the DC will receive hands-on training in co-culture techniques and functional immuno-oncology assays to assess the biological relevance and therapeutic potential of the selected targets.
Results
- An overview of deregulated immune pathways in NET.
- A catalogue of potential non-canonical immunogenic targets.
- Prioritization & validation of candidates for further preclinical development.
DC2 - Dissection of naturally presented hidden immunopeptidomic landscapes in NET at The Institute of Cancer research, London
Performing immunopeptidomics on patient-derived tissues to identify immunogenic, naturally presented peptides that could be used as NET-specific targets at the Institute of Cancer Research, London, under the supervision of Prof. Dr. Jyoti Choudhary.
Work Plan
- Performing immunopeptidomics on patient-derived tissue (n=10 per subtype) to identify immunogenic, naturally presented peptides that could be used as NET-specific targets. - Integrating in-house developed in silico tools with T-cell receptor (TCR)
- peptide major histocompatibility complex (pMHC) modelling (using TCR sequencing data generated by DC7), to predict the immunogenicity of the identified targets. For this, the DC will learn to use the company’s T-cell recognizability pipelines as well as publicly available AI-driven docking tools during a secondment to IW.
- After cross-validation against the targets identified by DC1, the top 3 most confidence targets will be in vitro validated using newly developed co-cultures of NET tumoroids with immune components. For this, the DC will get training in establishing NET tumoroids, co-culture techniques and immuno-oncology assays during a secondment to LUM, together with DC12.
Results
- A catalogue of prioritized immunogenic targets.
- SOPs for establishing tumoroids- effector cell co-cultures.
- SOPs for combining in silico with in vitro experiments for prioritization of targets for indirect immune driven strategies.
DC3 - Development of NET-directed -CAR-NK cell therapy at the University of Antwerp
The overall aim of this project is to provide a proof-of-principle for the use fourth-generation IL-15-secreting CAR NK cells for the treatment of NET using stablished NET specific targets at the University of Antwerp, under the supervision of Dr. Jonas Van Audenaerde and Prof. Dr. Timon Vandamme.
Work Plan
Establishing both human and murine chimeric antigen receptor (CAR) natural killer (NK) cells directed towards established NET specific targets. Assessing the preclinical therapeutic feasibility of a CAR-based strategy for NET using both in vitro and in vivo models. Investigating the mechanisms governing CAR NK cell activation, tumor-cell recognition, and effector functions in the context of NET using in vivo models. Developing a clinical development plan for CAR-NK cellular therapy in NET by performing a gap analysis between existing preclinical data and required regulatory/ manufacturing requirements needed for approval to initiate a phase 1 clinical trial.
Most of the work will be performed at the centre for oncological research (CORE) at the university of Antwerp, Belgium. During the course of the project, the candidate will be trained in the handling and experimental use of the RIP-tag2 mice during a secondment at IDIBELL, bareclone, Spain. Moreover, during a secondment to SGS, Antwerp, Belguim the candidate will get hands-on experience with regulatory requirements and clinical trial design, needed to draft a clinical development plan for CAR-NK cell therapy for NET.
Results
- Human and murine CAR-NK cells dericted to etablished NET targets.
- Preclinical efficacy of CAR-NK cell therapy in NET
- Mechanistic insights into the interaction between CAR NK cells, the neuroencrine tumor cells and itheir microenvironment
- Clinical development plan for CAR-NK cell therapy for NET and synopsis for First-In-Human Trial
DC4 - Development of SSTR2-targeting dendritic cell therapy for NET at Erasmus University Medical Center Rotterdam
Leveraging existing datasets and in silico tools to identify immunogenic human SSTR2-derived peptide epitopes for dendritic cell-based therapy, followed by the development of SSTR2-loaded dendritic cells using the most promising epitopes and evaluation of their therapeutic efficacy in NET-specific preclinical models at the Erasmus MC Cancer Institute under the supervision of Prof. Dr. Joachim Aerts.
Work Plan
- Utilizing available datasets to identify immunogenic peptide epitopes derived from the extracellular domains of the human SSTR2 receptor for dendritic cell therapy.
- During a secondment at MN the DC will learn to use MN’s in silico tools to prioritize immunogenic epitopes of the extracellular domain of SSTR2. Autologous monocyte-derived dendritic cells will be loaded with peptides synthesized based on the most promising SSTR2 epitopes and characterized for phenotype, matruration status and antigen-presentation capacity using functional testing. Performing in vitro efficacy testing of SSTR2-loaded dendritic cells. To do so, autologous T cells will first be primed by SSTR2-loaded dendritic cells and evaluated using immune activation assays. Subsequently, SSTR2-expressing NET cell lines will be co-cultured with T cells primed by SSTR2-loaded DCs to assess tumour-cell killing.
- During a secondment to SGS, the DC will get hands-on experience with regulatory requirements and clinical trial design, needed to draft a clinical development plan for dendritic cell therapy for NET.
Results
- Prioritized and in vitro validated extracellular and immunogenic epitopes of SSTR2.
- Development of a human dendritic cell vaccine against NET.
- SOPs for establishing cell line-T-cell co-cultures.
- Clinical development plan for the dendritic cell vaccine and synopsis for First-In-Human Trial.
DC5 - Mapping the cell-surface landscape of NET to explore the use of antibody-drug conjugates (ADC) and bi-specific T-cell engagers (BiTE) for precision-based immunotherapy at Erasmus University Medical Center Rotterdam
Performing spatial proteomics on available tissue micro arrays (TMA) to identify novel cell-surface protein-based targets that can be used for ADC- or BiTE-based therapies, followed by preclinical efficacy testing of the most promising targets using NET-specific preclinical models at the Erasmus MC under the supervision of Prof. Dr. Ernst-Jan Speel.
Work plan
- Performing spatial omics on available tissue micro arrays (TMA, n=100 per subtype). Identify novel cell-surface protein-based targets (that can be used for ADC- or BiTE-based therapies) by combining this data with available transcriptomics data.
- To prioritize the best targets based on their biological relevance, the DC will gain in-depth insight into the pathophysiology of pNET and small intestine NET (siNET) and lung NET (LNET) at EMC, during a secondment to INSERM. Protein-level expression validation will provide further biological target prioritization.
- Translational validation based on the availability of ADCs or BiTEs already in (pre)clinical development in other cancer types, will provide a shortlist of targets and corresponding targeted therapies for further efficacy testing. For this, the DC will learn how to run high-throughput screens using the ex vivo patient tissue (EVPT) platform developed by DC13 during a secondment at CB.
Results
- A comprehensive map of TIME with a focus on spatial distribution of TIME components.
- catalogue of prioritized cell-surface protein-based targets.
- SOPs for combining in silico with in vitro experiments for prioritization of targets for direct immune driven strategies.
- Preclinical efficacy of selected ADCs and BiTEs in NET subtypes.
DC6 - Establishing neoantigen-reactive tumor-infiltrating lymphocytes [TILs] as an adoptive cell therapy for NET at Libera Università Mediterranea Giuseppe Degennaro
Selecting and expanding NET specific neoantigen-reactive TILs and evaluate the efficacy in NET specific preclinical models at Libera Università Mediterranea Giuseppe Degennaro under the supervision of Prof. Dr. Mauro Cives.
Work plan
- Selecting and expanding neoantigen-reactive TILs to clinically meaningful numbers so that they can be used as adoptive cell therapy for NET. By co-incubating these TILs with autologous dendritic cells loaded with synthetic peptides harboring neo-epitope sequences and performing immuno-oncology functional assays, the potential of inducing immunogenic cell death will be validated. Moreover, the antitumor potential of these validated neoantigen-reactive TILs will be evaluated by co-incubating them with NET tumoroids.
- During a secondment at ICR, DC will learn single cell RNA sequencing (scRNAseq) and advanced mass spectrometry techniques which will be used to get insight into the mechanisms of efficacy or resistance of the neoantigen-reactive TILs.
- During a secondment to SGS, the DC will get hands-on experience with regulatory requirements and clinical trial design, needed to draft a clinical development plan for adoptive cell therapy for NET.
Results
- An adoptive cell therapy for NET based on neoantigen-reactive TILs.
- Preclinical efficacy of neoantigen-reactive TILs cells.
- Potentially actionable TIME-related determinants of TIL-based immunotherapy efficacy
- Clinical development plan for (novel) immune-driven therapies and synopsis for First-In-Human Trial.
DC7 - Assessing naturally occurring immune surveillance against NET at the University of Antwerp
In-depth profiling of the cellular composition of the TIME with specific emphasis on the TCR repertoire on patient-derived tissues at the University of Antwerp under the supervision of Prof. Dr. Timon Vandamme.
Work plan
- Expanding, harmonizing, and centralizing collection of fresh frozen NET tumor tissue and PBMC samples at UZA and other CoEs, ensuring compliant sampling and proper logistics.
- In-depth profiling of the cellular composition of the TIME with specific emphasis on the TCR repertoire on patient-derived tumor tissues and peripheral blood mononuclear cells of different NET subtypes.
- Applying advanced bioinformatics approaches to identify NET-specific TCR clonotypes and epitopes, track clonal evolution, and prioritize candidate tumor-reactive TCRs to guide the development of future TCR-T cell therapies.
- Applying advanced bioinformatics approaches to get insight into the mechanistic basis of immune evasion and themetastatic potential of different NET subtypes.
Results
- A comprehensive map of the TCR repertoire present in the TIME and circulating immune cells across NET subtypes.
- Potentially actionable determinants of immune evasion and metastatic potential.
- A catalogue of tumor-reactive TCRs for immune-driven target exploitation.
DC8 - Remodeling the TIME to prime siNET at the University Claude Bernard Lyon 1
Comprehensively characterizing the immune cell and cancer-associated fibroblast (CAF) landscape in patient-derived small intestinal NET (siNET) tissues and functionally investigating how CAF–immune cell interactions contribute to immune exclusion in siNET at the University Claude Bernard Lyon 1 under the supervision of Dr. Yenkel Grinberg-Bleyer.
Work plan
- Comprehensively mapping the landscape of immune cells and cancer-associated fibroblast (CAF) subsets on patient-derived siNET tissues (n=10). This will be done during a secondment at UAntwerp, where the DC will learn in-depth profiling of the cellular composition. In silico data processing and clustering will identify putative CAF- and immune-based interactions responsible for poor immunotherapy responsiveness, and the most promising interactions will be validated on patient-derived siNET tissues.
- During a secondment to CB the DC will get hands-on training on applying the ex vivo screening platform developed by DC13, allowing medium-throughput functional assays to further investigate the role of these CAF- and immune-based interactions in immune exclusion.
Results
- A multi-platform atlas of the complexity of the TIME of siNET.
- A catalogue of CAF- and immune-based interactions responsible for poor immunotherapy responsiveness.
- SOPs for combining in silico and in vitro experiments for discovery of actionable strategies for TIME modulation.
DC9 - Using bioengineered cytokine therapy to prime NET and improve immunotherapy efficacy at The Institute of Cancer Research, London
Establishing new syngeneic in vivo models with intact immune system and co-culture in vitro models allowing to recapitulate the different immune infiltration patterns present within NET and use these models to test the potential of collagen-binding (CBD)-IL-12 and/or other therapies to prime the tumour-immune microenvironment in NET by enhancing the immune infiltration at The Institute of Cancer Research, London, under the supervision of Prof. Dr. Anguraj Sadanandam.
Work plan
- Establishing new syngeneic in vivo models with intact immune system and in vitro co-culture systems allowing to recapitulate the different immune infiltration patterns present within pNET (metastasis-like primary [MLP] and non-MLP tumors). For this, the DC will be trained in the handling and experimental use of a) RIP-tag2 mice and b) multiple syngeneic (intrapancreatic) transplantation models using cell lines derived from genetically-engineered and modified RIP-Tag2 mice during a secondment at IDIBELL.
- Assessing the anti-tumor efficacy of collagen-binding (CBD)-IL-12, alone and in combination with ICIs. In-depth TIME profiling of treated and control tumors will elucidate cellular and molecular mechanisms driving treatment responses.
- During a secondment at OA, the DC will be trained in machine-learning approaches focusing on cross-species analyses between the murine and available human datasets, which will identify conserved immune remodeling signatures.
Results
- Validated protocols for establishing novel in vivo and in vitro models.
- Preclinical efficacy of CBD-IL-12 (in combination with immunotherapy).
- A comprehensive TIME map across NET subtypes, integrating human and murine data.
DC10 - Peptide receptor radiotherapy [PRRT]-induced increase in mutational burden to prime NET the University Claude Bernard Lyon 1
Investigating the impact of SSTR-targeted peptide receptor radionuclide therapy (PRRT) on the tumor immune microenvironment in NET, with a particular focus on neoepitope formation at the University Claude Bernard Lyon 1, under the supervision of Dr. Benjamin Gibert.
Work plan
- Identifying SSTR-based PRRT-treatment-induced changes in NET, that lead to resitance and neo-epitopes formation. For this, the DC will be trained in performing immunopeptidome analysis on human pre- and post PRRT samples during a secondment at ICR and analyzed in complementarity with DC2.
- Investigating the dynamics of TIME evolution in pre- and post-PRRT samples. - During a secondment at OD, the impact of the company’s innovative alpha-emitting PRRT-treatment on TIME will be investigated.
Results
- The identification of PRRT-induced resistance.
- A comprehensive reference map describing the of the TIME before and after PRRT treatment.
- The impact of alpha-PRRT as modulator of TIME.
DC11 - Mapping chemo-induced changes that could prime NET at Inserm
In depth characterizing the immune and stromal infiltrates and their spatial distribution in paired human samples before and after chemotherapy treatment at Institut National De La Sante Et De La Recherche Medicale (Inserm), under the supervision of Prof. Dr. Jerome Cros.
Work plan
- Characterizing the immune and stromal infiltrates and their spatial distribution in paired human samples before and after chemotherapy treatment. This data will be integrated with complementary TCR sequencing data, to study how chemo-induced hypermutation affects clonal diversity and repertoire dynamics. For this, advanced training in bioinformatics will be provided through a secondment at IW where the DC will learn how to use the company’s T- cell recognizability pipelines.
- During a secondment at IDIBELL, the DC will learn to establish syngeneic xenografts using cell lines, hypermutated through chemotherapy exposure. This new in vivo model will be used to evaluate the efficacy of ICI after chemotherapy-induced TIME priming.
Results
- A comprehensive map of TIME across NET subtypes, focused on chemo-induced NET TIME remodeling.
- Validated protocols for establishing a novel in vivo model.
- Proof-of-concept for immune-priming through chemo-induced TIME remodeling.
- Preclinical efficacy of immunotherapy after TIME priming.
DC12 - Manipulating the splicing mechanism to prime NET trough increased neoantigen burden at the University of Cordoba
Exposing NET tumoroids and cell lines to a panel of late-stage splicing inhibitors and asses their potential to generate splicing-derived neoantigens at the University of Cordoba under the supervision of Prof. Dr. Justo P. Castaño.
Work plan
- Exposing NET tumoroids and cell lines to a panel of late-stage splicing inhibitors (Pladienolide-B, H3B-8800, OTX015, GSK3368715, GSK3326595, and Indisulam) and asses their potential to generate splicing-derived neoantigens. These newly formed neoantigens could be used as NET-specific targets.
- During a secondment at MN, the DC will be trained to use the company’s immunogenicity prediction workflows needed to model the immunogenic potential of the newly formed neoantigens.
- This is complemented with in vitro validation assays using newly developed co-cultures of NET tumoroids with immune components. For this, the DCs will get training in establishing NET tumoroids, co-culture techniques and immuno-oncology assays during a secondment at LUM.
Results
- Proof-of-concept for immune-priming through splicing-induced neoantigen generation.
- A catalogue of prioritized NET-specific splicing-derived targets.
- SOPs for combining in silico with in vitro experiments for optimal prioritization of targets for indirect immune driven strategies.
- SOPs for establishing tumoroids- effector cell co-cultures.
DC13 - Ex vivo drug screening platform (EVPT) for NET allowing for high value, high-throughput drug testing at Crown Bioscience Netherlands
Establishing an EVPT platform that allows advanced drug screening in a 3D setting in presence of the native TIME at Crown Bioscience Netherlands under the supervision of Dr. Marrit Putker.
Work plan
- Establishing an EVPT platform that allows advanced drug screening in a 3D setting in presence of the native TIME.
- An early secondment at UZA will provide training on tissue harvesting processes and provides opportunity to optimize tissue sourcing, storing and shipping procedures of fresh patient-derived NET tissues.
- The platform will be validated by evaluating the cytotoxic and immune-activation capacity of standard-of-care drugs for NET and established immune-driven strategies (such as ICIs). Innate mechanisms of resistance against immunotherapeutic drugs will be investigated, linking functional response data with genomic and spatial data generated by DC6,7,8 to uncover TIME-associated determinants of treatment failure and identify actionable strategies overcome them. For this, advanced training in spatial NGS technologies and bioinformatic analysis will be provided through a secondment at EMC.
Results
- SOPs to harmonize fresh tissue sourcing, storing and shipping across participating CoEs.
- A standardized EVPT NET drug testing platform for short-term ex vivo drug testing and commercial application.
- Actionable TIME-associated determinants of NET’s unresponsiveness towards classical immune-driven strategies.
DC14 - Development of immunocompetent NET mouse models incorporating patient-derived CAFs at Crown Bioscience Netherlands
Establishing and phenotypically and transcriptomically profile patient-derived NET CAF lines, co-culture them with patient-derived tumor tissue and engrafted them into immunocompetent humanized mouse models to generate novel in vivo humanized NET PDX models at Crown Bioscience Netherlands under the supervision of Dr. Marrit Putker.
Work plan
- Establishing and phenotypically and transcriptomically profile patient-derived NET CAF lines. For this, advanced training in bioinformatics will be provided through a secondment at EMC.
- A second secondment at EMBL will provide training in (triple) co-culturing patient-derived tumor tissue with the established patient-derived CAF lines. These co-cultured cells will subsequently be engrafted into immunocompetent humanized mouse models.
- These in vivo humanized NET PDX models will be used to test late-stage development immune-oncology therapies (including the targeted therapies identified by DC5) as well as newly developed immuno-oncology therapies (developed by DC3, DC4 and DC6; if available).
Results
- A comprehensive map of the CAF component of the TIME across NET subtypes.
- Validated protocols for establishing novel in vivo immunocompetent models faithfully recapitulating the human TIME.
- Proof-of-concept for the repurposing late-stage development immune-oncology therapies towards NET as well as in vivo efficacy of novel immune-based strategies developed/identified.
DC15 -Organoid-immune co-cultures as a modular assay platform to study tumor-TIME interactions at European Molecular Biology Laboratory
Establishing a biobank of patient-derived tumor organoids (PDTOs) representing multiple NET subtypes, developing co-culture models incorporating diverse cell types, including immune and stromal populations, and functionally and molecularly characterizing these novel ex vivo preclinical models at European Molecular Biology Laboratory (EMBL), under the supervision of Dr. Talya Dayton.
Work plan
- Optimizing tissue sourcing, storing and shipping procedures of fresh patient-derived NET tissues, which will be used to establish a biobank of NET patient-derived tumor organoid (PDTOs) across multiple NET subtypes. Building on these PDTOs, multicellular co-cultures including immune/stromal cell populations components will be established.
- During a secondment to CB, the DC will receive training in preclinical functional assays needed to characterize these models. By complementing this with molecular characterization, the DC will comprehensively map how TIME components influence tumor phenotype and vice versa.
- Integrating in depth functional response analysis following CRISPR-based tumor engineering, tumor-intrinsic factors that modulate immune evasion and suppression will be identified.
- During a secondment at UCBL, the DC will be trained in multi-omics and machine-learning approaches to dissect specific interactions between tumor organoids and immune/stromal cell populations.
Results
- SOPs to harmonize fresh tissue sourcing, storing and shipping across participating CoEs.
- SOPs for establishing (co-cultures of) PDTOs of NET subtypes and use these in a modular assay platform combining genetic engineering and quantitative phenotyping.
- A catalogue of actionable strategies for TIME modulation to counter immune evasion and suppression.
Additional information
Benefits
All positions are full-time employment contracts of 36 months, with full social security coverage, under the rules of the Marie Skłodowska-Curie Actions. These are salaried positions, not stipends, fellowships or scholarships. The salary follows the MSCA Doctoral Network rules for the 2025 call. The exact gross salary depends on the host country. The salary has a living allowance and a mobility allowance, plus a family allowance if you have family obligations at the time of recruitment. In addition you will receive:
- Supervision by a world-leading, interdisciplinary supervisory team from different dIscOverNET partners, consisting of three supervisors per DC.
- Two secondments at dIscOverNET partner organisations, of a combined duration of 7–10 months.
- A structured training program: including interdisciplinary and intersectoral trainings, research and transferabls skills trainings, international workshops and conferences.
- Enrolment in a doctoral program leading to a PhD.
- A competitive set of benefits defined by the employment conditions of the host institution, such as paid leave and pension arrangements.
Equal opportunities
dIscOverNET and its partners recruit in an open, transparent, and merit-based way, in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. We welcome applications from all qualified candidates regardless of gender, age, ethnic or national origin, religion or belief, disability, sexual orientation, or any other characteristic, which is why we will not ask for your first name when you apply as a candidate for this project. We aim for a gender-balanced cohort.
The Application Process
How it works
You apply for up to 3 of the 15 Research Projects via the application form of this website. You can indicate your project preference (first, second or third) per project you apply for in each separate application form. Every project you apply for will consider you, not only your first choice, so applying for more than one project simply widens your options. Applying to more than three projects however, makes all your applications ineligible. After the deadline, the supervisory team of every Research Project reviews all applications, and the top three candidates are invited for an in-person interview on Thursday 29 April at Antwerp, Belgium.
Before you apply: are you eligible?
dIscOverNET follows the eligibility rules of the Marie Skłodowska-Curie Actions.
These are the following:
- you do not already hold a doctorate (PhD),
- you will have a master’s degree, or an equivalent that gives access to doctoral study, by the time you start,
- you must not have lived, worked or studied in the country of your chosen host for more than 12 months in the three years before you would be recruited (the mobility rule, and short stays such as holidays do not count),
- applicants of any nationality are welcome.
If you are not sure whether you qualify, you can check the FAQ, or you can contact us before you apply.
How to apply and what you will need
To apply, please send an email to dIscOverNET@uantwerpen.be with all the required documents, including the application form specific to the Research Project you are applying for, in PDF format.
You can find the application form for every Individual Research Project by clicking on the expandable box per DC above.
Please use "dIscOverNET application {number of the research project you are applying for} {your last name} {1st, 2nd or 3rd choice}" as the title for your email and include the following documents:
- Application form (see above) including:
- a few short eligibility questions,
- your motivation for the Research Project you apply for (150 to 200 words),
- a rating and short description of your experience with the key techniques of the project.
- Your CV, which should clearly state the following:
your LAST NAME ONLY,
- your academic record,
- your research experience (projects, methods, and results),
- any publications and awards.
- Copy of your highest completed degree.
- Valid ID.
- Proof of eligibility for the MSCA DN Mobility Rule (see more information above 'Are you eligible?').
- An overview of your bachelor's and master's grades.
If you have a proof of English language proficiency, such as a language degree and/or certificate, please add this to your application as well.
Reference letters are not needed when you apply. We will ask for your referees' details if you progress to the later stages of selection.
The closing date for applications is 17 January 2027.
The recruitment process
Every application is assessed on academic excellence, research potential and motivation, communication skills, and international experience. Recruitment is open, transparent and based on merit, conducted in line with the European Charter for Researchers, with attention to gender balance and equal opportunity, which is why we will not ask for your first name when you apply as a candidate for this project.
The interviews and final selection of the top three candidates will take place on Thursday 29 April at Antwerp, Belgium. Please make sure that you are available during those dates for the selection process to take place. dIscOverNET will offer financial support of max. € 350 to attend this physical event. If however, physical attendance is not possible, a virtual meeting will be set up.
Not being able to attend the interview in person will not count against you.
The recruitment process of DCs within dIscOverNET is in line with the principles set out in the European Charter for Researchers.
Recruitment timeline
- 24 November 2026, 0:00 CET: applications open
- 17 January 2027, 23:59 CET: applications close
- 18 January - 10 March 2027: assessment and shortlisting of the top three candidates
- 15-19 March 2027: inform all candidates
- Thursday 29 April 2027: interviews and selection of the final top three candidates, which will take place at Antwerp
- September / October 2027: planned start (at the latest 1 December 2027, depending on the host institution)
The recruitment process takes several weeks, so a period without news is not a negative sign. Every applicant is informed of the outcome, which will normally be between 15 and 19 March 2027.
Additional comments
Questions about the positions or the procedure: please check our FAQ first, as it answers most questions.
For anything else, contact Karolien van Dessel, dIscOverNET project manager, via dIscOverNET@Uantwerpen.be.
This position is funded by the European Union under the Marie Skłodowska-Curie Actions Doctoral Networks, Horizon Europe (Grant Agreement No. 101311447). Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.